CS-121 vs Plozasiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Familial Chylomicronemia Syndrome
Shared mechanism: APOC3 · full Familial Chylomicronemia Syndrome pipeline
CS-121
Developed by CorrectSequence Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07176923 (registry estimate)
No aligned efficacy figure on record for this race.
Plozasiran · Redemplo
Marketed by Arrowhead Pharmaceuticals and partners
NCT05089084 · Phase 3 · completed
The study randomly assigned 75 participants to plozasiran or placebo and used quadruple masking, with 25 mg, 50 mg, and pooled placebo groups. The primary fasting-triglyceride endpoint was statistically significantly improved for both doses, but it was a laboratory surrogate rather than a hard clinical or endoscopic outcome, supporting a moderate grade.
Reported efficacy
Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) (met)
Result source: NCT05089084
Results for Familial Chylomicronemia Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
CS-121: no structured comparison results are available for Familial Chylomicronemia Syndrome.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Plozasiran
show 5 more results
show 3 more results
show 3 more results
Available safety results
Plozasiran
| Dropout rate | 11.5%25 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result8.3%50 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
|---|---|
| Discontinued due to AEs | 7.7%25 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result4.2%50 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
| Serious AEs | 19.2%25 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result8.3%50 mg NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
| Most frequent reported AEs | 25 mg abdominal pain 26.9% (placebo 28%) covid-19 19.2% (placebo 4%) nasopharyngitis 19.2% (placebo 16%) NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 show 1 more result50 mg abdominal pain 29.2% (placebo 28%) covid-19 29.2% (placebo 4%) headache 20.8% (placebo 8%) NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3 |
Severe Hypertriglyceridemia
Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline
CS-121
Developed by CorrectSequence Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07657780 (registry estimate)
No aligned efficacy figure on record for this race.
Plozasiran · Redemplo
Marketed by Arrowhead Pharmaceuticals and partners
NCT06347003 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: March 2029 · NCT06880770 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Severe Hypertriglyceridemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
CS-121: no structured comparison results are available for Severe Hypertriglyceridemia.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Plozasiran
show 29 more results
show 56 more results
show 29 more results
show 29 more results
show 29 more results
Available safety results
Plozasiran
| Dropout rate | 7%50 mg NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results5.5%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 9.1%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 1.8%50 mg NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results0%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 1.8%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.5%50 mg NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results3.6%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 7.4%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 50 mg covid-19 16.1% (placebo 14.8%) upper respiratory tract infection 12.5% (placebo 6.6%) type 2 diabetes mellitus 10.7% (placebo 4.9%) NCT04720534 · Phase 2 · registry result, not featured evidence show 2 more results25 mg covid-19 16.4% (placebo 14.8%) headache 10.9% (placebo 4.9%) sinusitis 7.3% (placebo 0%) NCT04720534 · Phase 2 · registry result, not featured evidence 10 mg covid-19 20.4% (placebo 14.8%) headache 14.8% (placebo 4.9%) urinary tract infection 11.1% (placebo 9.8%) NCT04720534 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CS-121's landscape · Plozasiran's landscape